Company Profile

Biocorp specializes in the development and manufacture of medical devices and drug delivery systems. The company offers traditional delivery systems, connected injection systems and monitoring devices. Net sales break down by source of income between sales of services (86.9%) and products (13.1%). At the end of 2022, Biocorp has a production site located in France. France accounts for 62.6% of net sales.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

02/10/23	Biocorp: Novo Nordisk exceeds 90% of share capital
29/09/23	Biocorp: Novo Nordisk holds 97.8% of the capital
07/09/23	Biocorp: simplified tender offer opened on September 7
06/09/23	Biocorp: AMF gives go-ahead to proposed simplified tender offer
04/09/23	Biocorp Production Reports Earnings Results for the Half Year Ended June 30, 2023	CI
07/08/23	CAC40: anecdotal rise, caution prevails
07/08/23	CAC40: hovering around 7300 pts, low volumes
07/08/23	CAC40: regains some color and crosses 7300 pts
07/08/23	CAC40: Caution prevails as the week begins with a slight decline
07/08/23	Biocorp: takeover by Novo Nordisk completed
07/08/23	Denmark's Novo Nordisk Closes Biocorp's Controlling Stake Deal	MT
04/08/23	Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of a 64.4% stake in Biocorp Production from Vatel Capital SAS, Nyenburgh Investment Partners, BIO JAG and Greenstock	CI
19/06/23	Global markets live: Airbus, Intel, Meta Platforms, Berkshire Hathaway...

28/08/23	Biocorp : Franchissement de seuil	PU
07/12/22	BIOCORP Obtains 510(k) FDA Clearance for Mallya	AQ
20/09/21	Biocorp : Upcoming investor meetings	PU
16/09/21	BIOCORP : and MERCK KGaA sign a partnership in the field of Human Growth Hormone	PU
13/04/21	BIOCORP : and ROCHE DIABETES CARE FRANCE launch Mallya in France	PU

20/11/24	PLFSS 2025: le gouvernement veut actionner la clause de sauvegarde sur les dispositifs médicaux
08/11/23	Medtech: les industriels demandent une "réforme globale" de la réglementation européenne
02/10/23	Biocorp : Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
02/10/23	Biocorp : Novo Nordisk dépasse les 90% du capital
29/09/23	Biocorp : Novo Nordisk détient 97,8% du capital

Manager	Title	Age	Since
Stéphane Chabanais DFI	Director of Finance/CFO	-	-
Sylvaine Dessard SAM	Sales & Marketing	-	-
Arnaud Guillet PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Emilie Gardette BRD	Director/Board Member	-	12/05/2015
Julien Gardette BRD	Director/Board Member	-	12/05/2015
Jean-Yves Berthon BRD	Director/Board Member	-	12/05/2015

Biocorp Stock

Stocks

ALCOR

FR0012788065

Advanced Medical Equipment & Technology

Latest news: Biocorp

Press Releases: Biocorp

News in other languages: Biocorp

Managers and Directors: Biocorp

Latest insider transactions

Other Advanced Medical Equipment & Technology

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/09/23	Eric Dessertenne	Buy	Chief Executive Officer	6,000	0.1360%
20/09/23	Eric Dessertenne	Buy	Chief Executive Officer	7,450	0.1688%
19/09/23	Eric Dessertenne	Buy	Chief Executive Officer	30,000	0.6799%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOCORP	-.--%	-.--%	-	-	173M
THERMO FISHER SCIENTIFIC, INC.	+0.28%	+1.33%	+28.79%	+18.50%	225B
DANAHER CORPORATION	+1.28%	-1.24%	+7.51%	-20.04%	141B
INTUITIVE SURGICAL, INC.	+2.17%	+7.56%	-13.22%	+24.00%	130B
BOSTON SCIENTIFIC CORPORATION	+4.85%	+0.17%	-54.89%	-14.86%	62.29B
SIEMENS HEALTHINEERS AG	+1.99%	+0.96%	-18.45%	-13.93%	49.39B
EDWARDS LIFESCIENCES CORPORATION	+1.87%	-1.23%	+12.62%	+15.71%	48.63B
AGILENT TECHNOLOGIES, INC.	-0.54%	-0.46%	+16.35%	+27.24%	41.42B
WATERS CORPORATION	-0.20%	+0.95%	+36.01%	+49.53%	40.12B
RESMED, INC.	+2.27%	+0.90%	-17.76%	+51.07%	31.23B
Average	+1.44%	-3.23%	-0.34%	+15.25%	85.52B
Weighted average by Cap.	+1.40%	-2.40%	+4.78%	+10.84%